late
decemb
cluster
pneumonia
case
caus
novel
coronaviru
cov
report
wuhan
china
genom
sequenc
show
pathogen
coronaviru
ident
bat
coronaviru
share
sequenc
identifi
sarscov
novel
coronaviru
name
sever
acut
respiratori
syndrom
coronaviru
intern
committe
taxonomi
virus
pneumonia
design
world
health
organ
februari
epidem
spread
rapidli
countri
announc
global
health
emerg
clinic
effect
vaccin
specif
antivir
drug
current
avail
prevent
treatment
infect
combin
antihiv
drug
lopinavirritonavir
use
cur
effect
remain
limit
toxic
side
effect
remdesivir
broadspectrum
antivir
drug
develop
gilead
scienc
inc
also
explor
treatment
data
need
prove
efficaci
specif
drug
effici
safeti
urgent
need
maximum
likelihood
tree
base
genom
sequenc
show
viru
fall
within
subgenu
sarbecoviru
genu
betacoronaviru
coronavirus
envelop
positivesens
singlestrand
rna
virus
genom
rna
cov
approxim
k
nt
length
structur
tail
contain
least
open
read
frame
orf
first
orf
orf
twothird
genom
length
directli
translat
two
polyprotein
frameshift
polyprotein
process
main
proteas
mpro
also
known
proteas
one
two
papainlik
proteas
plp
nonstructur
protein
nsp
nsp
engag
product
subgenom
rna
encod
four
main
structur
protein
envelop
e
membran
spike
nucleocapsid
n
protein
accessori
protein
therefor
proteas
especi
mpro
play
vital
role
life
cycl
coronaviru
mpro
threedomain
domain
iii
cystein
proteas
involv
matur
cleavag
event
within
precursor
polyprotein
activ
mpro
homodim
contain
two
protom
cov
mpro
featur
noncanon
cyshi
dyad
locat
cleft
domain
ii
mpro
conserv
among
cov
sever
common
featur
share
among
substrat
mpro
differ
cov
amino
acid
substrat
n
terminu
c
terminu
number
fellow
cleavag
site
particular
gln
residu
almost
alway
requir
posit
substrat
human
homolog
mpro
make
ideal
antivir
target
activ
site
mpro
highli
conserv
among
cov
mpro
usual
compos
four
site
analyz
substratebind
pocket
sarscov
mpro
pdb
id
novel
inhibitor
target
mpro
design
synthes
fig
thiol
cystein
residu
site
anchor
inhibitor
coval
linkag
import
inhibitor
maintain
antivir
activ
design
new
inhibitor
aldehyd
select
new
warhead
order
form
coval
bond
cystein
report
sarscov
mpro
inhibitor
often
ring
occupi
site
mpro
ring
expect
good
choic
furthermor
site
coronaviru
mpro
usual
larg
enough
accommod
bigger
fragment
test
import
differ
ring
system
cyclohexyl
introduc
fluorin
expect
enhanc
activ
indol
group
introduc
order
form
new
hydrogen
bond
improv
druglik
properti
synthet
rout
chemic
structur
compound
shown
scheme
start
materi
nboclglutam
acid
dimethyl
ester
obtain
commerci
supplier
use
without
purif
synthes
key
intermedi
accord
literatur
intermedi
synthes
acid
remov
tbutoxycarbonyl
group
yield
coupl
acid
yield
ester
peptidomimet
aldehyd
approach
twostep
rout
ester
deriv
first
reduc
gener
primari
alcohol
subsequ
oxid
aldehyd
dessmartin
periodinan
dmp
recombin
mpro
express
purifi
escherichia
coli
e
coli
fluoresc
label
substrat
dnp
deriv
ntermin
autocleavag
sequenc
viral
proteas
design
synthes
enzymat
assay
exhibit
high
mpro
inhibit
activ
reach
respect
use
fluoresc
reson
energi
transfer
fret
base
cleavag
assay
determin
valu
result
reveal
excel
inhibitori
potenc
valu
respect
fig
order
elucid
mechan
inhibit
mpro
determin
highresolut
crystal
structur
complex
resolut
tabl
crystal
belong
space
group
asymmetr
unit
contain
one
molecul
tabl
two
molecul
design
protom
protom
b
associ
homodim
around
crystallograph
symmetri
axi
fig
structur
protom
contain
three
domain
substratebind
site
locat
cleft
domain
ii
activ
site
mpro
cyshi
form
catalyt
dyad
fig
electron
densiti
map
clearli
show
compound
substrat
bind
pocket
mpro
extend
conform
fig
fig
b
detail
interact
shown
fig
b
c
electron
densiti
show
c
aldehyd
group
catalyt
site
mpro
form
standard
coval
bond
oxygen
atom
aldehyd
group
also
play
crucial
role
stabil
conform
inhibitor
form
hydrogen
bond
backbon
residu
site
ring
fit
well
site
oxygen
group
form
hydrogen
bond
side
chain
main
chain
side
chain
also
particip
stabil
ring
form
hydrogen
bond
nh
group
respect
addit
amid
bond
chain
hydrogenbond
main
chain
respect
cyclohexyl
moieti
deepli
insert
site
stack
imidazol
ring
cyclohexyl
group
also
surround
side
chain
produc
extens
hydrophob
interact
indol
group
expos
solvent
site
stabil
hydrogen
bond
side
chain
residu
interact
indol
group
hydrophob
interact
interestingli
multipl
water
molecul
name
play
import
role
bind
interact
amid
bond
hydrogen
bond
wherea
form
number
hydrogen
bond
aldehyd
group
residu
contribut
stabil
bind
pocket
crystal
structur
mpro
complex
similar
complex
show
similar
inhibitor
bind
mode
fig
fig
c
differ
bind
mode
probabl
due
group
compar
cyclohexyl
group
group
undergo
signific
downward
rotat
fig
side
chain
residu
interact
aryl
group
hydrophob
interact
side
chain
stabil
group
addit
hydrogen
bond
fig
e
f
short
two
crystal
structur
reveal
similar
inhibitori
mechan
compound
occupi
substratebind
pocket
block
enzym
activ
mpro
compar
sarscov
mpro
complex
structur
report
previous
bind
mode
mpro
complex
structur
similar
differ
among
overal
structur
small
fig
fig
b
f
differ
mainli
lie
interact
subsit
possibl
due
variou
size
function
group
correspond
site
inhibitor
fig
c
substanti
enzym
inhibit
result
evalu
abil
compound
inhibit
vitro
fig
fig
shown
fig
compound
exhibit
good
activ
cell
cultur
valu
use
plaquereduct
assay
respect
neither
compound
caus
signific
cytotox
half
cytotox
concentr
valu
yield
select
indic
si
respect
immunofluoresc
quantit
realtim
pcr
also
employ
monitor
antivir
activ
result
show
exhibit
good
antivir
effect
fig
fig
explor
druggabl
compound
compound
evalu
pharmacokinet
pk
properti
shown
tabl
compound
given
intraperiton
mgkg
intraven
mgkg
display
halflif
hour
hour
respect
high
maxim
concentr
cmax
ngml
good
bioavail
observ
compound
given
intraperiton
metabol
stabil
mice
also
good
clearanc
cl
mlminmg
administ
intraperiton
mgkg
subcutan
mgkg
intraven
mgkg
compound
also
show
good
pk
properti
bioavail
intraperiton
subcutan
longer
hour
given
intraperiton
consid
danger
select
intraven
drip
administr
studi
reason
valu
area
curv
auc
high
effect
rapid
compar
administr
intraven
shorter
clearanc
rate
faster
cl
mlminmg
compound
select
investig
intraven
drip
dose
spraguedawley
sd
rat
beagl
dog
result
show
tabl
exhibit
long
sd
rat
hour
beagl
dog
low
clearanc
rate
rat
mlminkg
dog
mlminkg
high
auc
valu
rat
hour
ngml
dog
hour
ngml
pk
result
indic
compound
worth
warrant
studi
vivo
toxic
studi
tabl
carri
sd
rat
beagl
dog
acut
toxic
measur
sd
rat
sd
rat
die
receiv
mgkg
intraven
drip
administr
dosag
rais
mgkg
one
four
sd
rat
die
dose
rang
toxic
studi
conduct
seven
day
dose
level
mgkg
sd
rat
mgkg
beagl
dog
anim
receiv
daili
dose
qd
intraven
drip
anim
clinic
observ
least
day
obviou
toxic
observ
either
group
data
indic
good
candid
clinic
studi
